From immunosuppression to tolerance

Journal of Hepatology

Volumn 62, Issue S1, 2015, Pages S170-S185

  Adams, David H ^b   Sanchez Fueyo, Alberto ^c   Samuel, Didier ^a  

^a INSERM   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Calcineurin inhibitors; Immune tolerance; Immunosuppression; mTOR inhibitors

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EFALIZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; OKT 3; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIGEN RECOGNITION; BILE DUCT; BLOOD GROUP ABO INCOMPATIBILITY; CHOLESTASIS; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; GRAFT FAILURE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; HYPERACUTE GRAFT REJECTION; IDIOPATHIC POSTTRANSPLANT HEPATITIS; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER BIOPSY; LIVER CELL; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NONHUMAN; PATIENT SELECTION; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SURGICAL PATIENT; ADVERSE EFFECTS; ANIMAL; GRAFT REJECTION;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 84947078226     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.042     Document Type: Review

References (142)

1. M. Olausson, L. Mjörnstedt, G. Norden, L. Rydberg, J. Mölne, L. Bäckman, and et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients Am J Transplant 7 2007 130 136
2. R. Ruiz, K. Tomiyama, J. Campsen, R.M. Goldstein, M.F. Levy, G.J. McKenna, and et al. Implications of a positive cross-match in liver transplantation: a 20-year review Liver Transpl 18 2012 455 460
3. H. Bismuth, D. Castaing, B.G. Ericson, J.B. Otte, K. Rolles, and B. Ringe Hepatic transplantation in Europe. First report of the European Liver Transplant Registry Lancet 2 1987 674 676
4. T.E. Starzl, S. Iwatzuki, D.H. Van Thiel, J.C. Gartner, B.J. Zitelli, and J.J. Malatack Evolution of liver transplantation Hepatology 2 1982 614 636
5. T.E. Starzl, A.J. Demetris, and D. Van Thiel Liver transplantation (first of two parts) N Engl J Med 321 1989 1014 1022
6. T.E. Starzl, A.J. Demetris, and D. Van Thiel Liver transplantation (second of two parts) N Engl J Med 321 1989 1092 1099
7. J. Campsen, M.A. Zimmerman, J.F. Trotter, M. Wachs, T. Bak, T. Steinberg, and et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticoid withdrawal Liver Transpl 14 2008 1281 1286
8. P.H. Thurairajah, M. Carbone, H. Bridgestock, P. Thomas, S. Hebbar, B.K. Gunson, and et al. Late acute liver allograft rejection: a study of its natural history and graft survival in the current era Transplantation 95 2013 955 959
9. M.R. Lucey, N. Terrault, L. Ojo, J.E. Hay, J. Neuberger, E. Blumberg, and et al. Long Term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of the Liver Diseases and the American Society of Transplantation Liver Transpl 19 2013 3 26
10. E.K. Geissler, and H.J. Schlitt Immunosuppression for liver transplantation Gut 58 2009 452 463
11. G.B. Klintmalm, G.L. Davis, L. Teperman, G.J. Netto, K. Washburn, S.M. Rudich, and et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C Liver Transpl 17 2011 1394 1403
12. R.A. Krom, C.H. Gips, H.J. Houthoff, D. Newton, D. Van der Waaj, J. Beelen, and et al. Orthotopic liver transplantation in Groningen, The Netherlands (1979-1983) Hepatology 4 1984 61S 65S
13. S. Karie-Guigues, N. Janus, F. Saliba, J. Dumortier, C. Duvoux, Y. Calmus, and et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study Liver Transpl 15 2009 1083 1091
14. K. Boudjema, C. Camus, F. Saliba, Y. Calmus, E. Salame, G. Pageaux, and et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. Standard-dose tacrolimus in liver transplantation: a randomized study Am J Transplant 11 2011 965 976
15. P. Manausou, E. Cholongitas, D. Samonakis, E. Tsochatzis, A. Corbani, A.P. Dhillon, and et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes Gut 63 2014 1005 1013
16. R.Y. Calne, K. Rolles, D.J. White, S. Thiru, D.B. Evans, P. McMaster, and et al. Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers Lancet 2 1979 1033 1036
17. A.J. Demetris, S. Lasky, D.H. Van Thiel, T. Starzl, and A. Dekker A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen Am J Pathol 118 1985 151 161
18. G. Levy, G.L. Grazi, F. Sanjuan, Y. Wu, F. Muhlbacher, D. Samuel, and et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus Liver Transpl 10 2006 1464 1472
19. T.E. Starzl, S. Todo, J. Fung, A.J. Demetris, R. Venkataramman, and A. Jain FK 506 for liver, kidney and pancreas transplantation Lancet 2 1989 1000 1004
20. The European FK 506 multicentre Study Group Randomized trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection Lancet 344 1994 423 428
21. J.G. O'Grady, A. Burroughs, P. Hardy, D. Elbourne, and A. Truesdale Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial Lancet 360 2002 1119 1125
22. J.M. Neuberger, R.D. Mamelok, P. Neuhaus, J. Pirenne, D. Samuel, H. Isionemi, and et al. Delayed introduction of reduced dose tacrolimus and renal function in liver transplantation: the ReSpECT study Am J Transplant 9 2009 327 336
23. O. Farges, B.G. Ericzon, S. Bresson-Hadni, S.V. Lynch, K. Höckerstedt, D. Houssin, and et al. A randomized trial of OKT3-based versus Cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian Multicenter study Transplantation 58 1994 891 898
24. A.B. Cosimi, S.I. Cho, F.L. Delmonico, M.M. Kaplan, R.J. Rohrer, and R.L. Jenkins A randomized clinical trial comparing OKT 3 and steroids for treatment of hepatic allograft acute rejection Transplantation 43 1987 91 95
25. T. Kawhara, S. Asthana, and N.M. Kneteman M-Tor inhibitors: what role in liver transplantation? J Hepatol 55 2011 1441 1451
26. G. Levy, H. Schmidli, J. Punch, E. Tuttle-Newhall, D. Mayer, P. Neuhaus, and et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results Liver Transpl 12 2006 1640 1648
27. F. Saliba, P. De Simone, F. Nevens, L. De Carlis, H.J. Metselaar, S. Beckebaum, and et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study Am J Transplant 13 2013 1734 1745
28. F. Saliba, S. Dharancy, R. Lorho, F. Conti, S. Radenne, M. Neau-Cransac, and et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis Liver Transpl 17 2011 905 913
29. P. De Simone, H.J. Metselaar, L. Fischer, J. Dumortier, K. Boudjema, J. Hardwigsen, and et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262 1269
30. A.O. Ojo, P.J. Held, F.K. Port, R.A. Wolfe, A.B. Leichtman, E.W. Young, and et al. Chronic renal failure after transplantation of a non renal organ N Engl J Med 349 2003 931 940
31. E.C. Verna, E.D. Farrand, A.S. Elnaggar, E.M. Pichardo, A. Balducci, J.C. Emond, and et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency Transplantation 91 2011 1254 1260
32. N. Selzner, D.R. Grant, I. Shalev, and G.A. Levy The immunosuppressive pipeline: meeting unmet needs in liver transplantation Liver Transpl 16 2010 1359 1372
33. D.N. Samonakis, G. Germani, and A.K. Burroughs Immunosuppression and HCV recurrence after liver transplantation J Hepatol 56 2012 973 983
34. W.D. Irish, S. Arcona, D. Bowers, and J.F. Trotter Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database Am J Transplant 11 2011 1676 1685
35. M. Berenguer, A. Royuela, and J. Zamora Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis Liver Transpl 13 2007 21 29
36. K.D. Watt, and M.R. Charlton Metabolic syndrome and liver transplantation: a review and guide to management J Hepatol 53 2010 199 206
37. S. Baid, A.B. Cosimi, M.L. Farrell, D.A. Schoenfeld, S. Feng, R.T. Chung, and et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality Transplantation 27 2001 1066 1072
38. E. Chak, and S. Saab Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review Liver Int 30 2010 1247 1258
39. K.D. Watt, R.A. Pedersen, W.K. Kremers, J.K. Heimbach, W. Sanchez, and G.J. Gores Long-term probability of and mortality from de novo malignancy after liver transplantation Gastroenterology 137 2009 2010 2017
40. T.A. Gonwa, M.L. Mai, L.B. Melton, S.R. Hays, R.M. Goldstein, M.F. Levy, and et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 27 2001 1934 1939
41. C. Duvoux, and G.P. Pageaux Immunosuppression in liver transplant recipients with renal impairment J Hepatol 54 2011 1041 1054
42. A. Sanchez-Fueyo, and T. Strom Immunological basis of graft rejection and tolerance following transplantation of liver or other solid organs Gastroenterology 140 2011 51 64
43. A. Shaked, R.M. Ghobrial, R.M. Merion, T.H. Shearon, J.C. Emond, J.H. Fair, and et al. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation Am J Transplant 9 2009 301 308
44. C. Tippner, B. Nashan, K. Hoshino, E. Schmidt-Sandte, K. Akimaru, K.H. Boker, and et al. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course Transplantation 72 2001 1122 1128
45. S. Shetty, D.H. Adams, and S.G. Hubscher Post-transplant liver biopsy and the immune response: lessons for the clinician Expert Rev Clin Immunol 8 2012 645 661
46. International Working Party Terminology for hepatic allograft rejection Hepatology 22 1995 648 654
47. Banff schema for grading liver allograft rejection: an international consensus document Hepatology 25 1997 658 663
48. Banff Working Group Liver biopsy interpretation for causes of late liver allograft dysfunction Hepatology 44 2006 489 501
49. J.M. Vierling, and R.H. Fennel Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts Hepatology 5 1985 1076 1082
50. J. Demetris, and et al. Update of the international Banff Schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection Hepatology 31 2000 792 799
51. J. Gugenheim, D. Samuel, M. Reynes, and H. Bismuth Liver transplantation across ABO blood group barriers Lancet 336 1990 519 523
52. S.J. Knechtle, P.C. Kolbeck, S. Tsuchimoto, A. Coundouriotis, F. Sanfilipo, and R.R. Bollinger Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection Transplantation 43 1987 8 12
53. A.J. Demetris, R. Jaffe, A. Tzakis, G. Ramsey, S. Todo, S. Belle, and et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers Am J Pathol 132 1988 489 502
54. O. Farges, A. Kalil, D. Samuel, F. Saliba, J.L. Arulnaden, P. Debat, and et al. The use of ABO-incompatible grafts in liver transplantation: a life saving procedure in highly selected patients Transplantation 59 1995 1124 1133
55. J. Lunz, K.M. Ruppert, M.M. Cajaiba, K. Isse, C.A. Bentlejewski, M. Minervini, and et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 12 2012 171 182
56. J.G. O'Leary, H.M. Gebel, R. Ruiz, R.A. Bray, J.D. Marr, X.J. Zhou, and et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation Am J Transplant 13 2013 954 960
57. A. Miyagawa-Hayashino, A. Yoshizawa, Y. Uchida, H. Egawa, K. Yurugi, S. Masuda, and et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts Liver Transpl 18 2012 1333 1342
58. J.G. O'Leary, H. Kaneku, L. Jennings, B.M. Susskind, P.I. Terasaki, and G.B. Klintmalm Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients Liver Transpl 20 2014 655 663
59. J.G. O'Leary, H. Kaneku, B.M. Susskind, L.W. Jennings, M.A. Neri, G.L. Davis, and et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Post-liver transplant Am J Transplant 11 2011 1868 1876
60. K.J. Wood, and R. Goto Mechanisms of rejection: current perspectives Transplantation 93 2012 1 10
61. J.G. O'Leary, H. Kaneku, A.J. Demetris, J.D. Marr, S.M. Shiller, B.M. Susskind, and et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss Liver Transpl 20 2014 218 227
62. J.G. O'Leary, H. Kaneku, L.W. Jennings, N. Bañuelos, B.M. Susskind, P.I. Terasaki, and et al. Preformed class II donor- specific antibodies are associated with an increased risk of early rejection after liver transplantation Liver Transpl 19 2013 973 980
63. A.I. Musat, R.M. Agni, P.Y. Wai, J.D. Pirsch, D.F. Lorentzen, A. Powell, and et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver Transplantation Am J Transplant 11 2011 500 510
64. A.J. Demetris, and K. Isse Tissue biopsy monitoring of operational tolerance in liver allograft recipients Curr Opin Organ Transplant 18 2013 345 353
65. J.G. O'Leary, A.J. Demetris, L.S. Friedman, H.M. Gebel, P.F. Halloran, A.D. Kirk, and et al. The role of donor-specific HLA alloantibodies in liver transplantation Am J Transplant 14 2014 779 787
66. J.G. O'Leary, S. Michelle Shiller, C. Bellamy, M.A. Nalesnik, H. Kaneku, L.W. Jennings, and et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features Liver Transpl 20 2014 1244 1255
67. S.S. Kelishadi, A.M. Azimzadeh, T. Zhang, T. Stoddard, E. Welty, C. Avon, and et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys J Clin Invest 120 2010 1275 1284
68. O.B. Herrera, D. Golshayan, R. Tibbott, F. Salcido Ochoa, M.J. James, F.M. Marelli-Berg, and et al. A novel pathway of alloantigen presentation by dendritic cells J Immunol 173 2004 4828 4837
69. R. Hanvesakul, N. Spencer, M. Cook, B. Gunson, M. Hathaway, R. Brown, and et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation Am J Transplant 8 2008 1931 1941
70. A.W. Thomson, and P.A. Knolle Antigen-presenting cell function in the tolerogenic liver environment Nat Rev Immunol 10 2010 753 766
71. T.L. Sumpter, J.G. Lunz, A. Castellaneta, B. Matta, D. Tokita, H.R. Turnquist, and et al. Dendritic cell immunobiology in relation to liver transplant outcome Front Biosci (Elite Ed) 1 2009 99 114
72. G. Alex Bishop, P.D. Bertolino, D.G. Bowen, and G.W. McCaughan Tolerance in liver transplantation Best Pract Res Clin Gastroenterol 26 2012 73 84
73. I.N. Crispe Liver antigen-presenting cells J Hepatol 54 2011 357 365
74. L.E. Holz, V. Benseler, M. Vo, C. McGuffog, N. Van Rooijen, G.W. McCaughan, and et al. Naive CD8 cell activation by liver bone marrow-derived cells leads to a "neglected" IL-2 low Bimhigh phenotype, poor CTL function and cells death J Hepatol 57 2012 830 836
75. V. Benseler, A. Warren, M. Vo, L.E. Holz, S.S. Tay, D.G. Le Couteur, and et al. Hepatocyte entry leads to degradation of autoreactive CD8 T cells Proc Natl Acad Sci U S A 108 2011 16735 16740
76. S.L. Swain, K.K. McKinstry, and T.M. Strutt Expanding roles for CD4+ T cells in immunity to viruses Nat Rev Immunol 12 2012 136 148
77. P.S. Heeger, N.S. Greenspan, S. Kuhlenschmidt, C. Dejelo, D.E. Hricik, J.A. Schulak, and et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes J Immunol 163 1999 2267 2275
78. T.S. Mele, N.M. Kneteman, L.F. Zhu, V. Ramassar, J. Urmson, B. Halloran, and et al. IFN-gamma is an absolute requirement for spontaneous acceptance of liver allografts Am J Transplant 3 2003 942 951
79. N. Obermajer, F.C. Popp, Y. Soeder, J. Haarer, E.K. Geissler, H.J. Schlitt, and et al. Conversion of Th17 into IL-17 A (neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy J Immunol 193 2014 4988 4999
80. Y. Wang, M. Zhang, Z.W. Liu, W.G. Ren, Y.C. Shi, Y.L. Sun, and et al. The ratio of circulating regulatory T cells (Tregs)/TH17cells is associated with acute allograft rejection in liver transplantation PLoS One 9 2014 e112135
81. Y.H. Oo, S. Shetty, and D.H. Adams The role of chemokines in the recruitment of lymphocytes in the liver Dig Dis 28 2010 31 44
82. C.N. Jenne, and P. Kubes Immune surveillance by the liver Nat Immunol 14 2013 996 1006
83. T. Martelius, V. Salaspuro, M. Salmi, L. Krogerus, K. Höckerstedt, S. Jalkanen, and et al. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection Am J Pathol 165 2004 1993 2001
84. S. Goddard, A. Williams, C. Morland, S. Qin, R. Gladue, S.G. Hubscher, and et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants Transplantation 27 2001 1957 1967
85. Y. Zhai, X.D. Shen, W.W. Hancock, F. Gao, B. Qiao, C. Lassman, and et al. CXCR3+CD4+Tcells mediate innate immune function in the pathophysiology of liver/ischemia reperfusion injury J Immunol 15 2006 6313 6322
86. Y.H. Oo, V. Banz, D. Kavanagh, E. Liaskou, D.R. Withers, E. Humphreys, and et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver J Hepatol 57 2012 1044 1051
87. A. Kahraman, F.J. Barreyro, S.F. Bronk, N.W. Werneburg, J.L. Mott, Y. Akazawa, and et al. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse Hepatology 47 2008 1317 1330
88. B. Eksteen, S.C. Afford, S.J. Wigmore, A.P. Holt, and D.H. Adams Immune-mediated liver injury Semin Liver Dis 27 2007 351 366
89. H. Tashiro, T. Itamoto, H. Ohdan, K. Arihiro, Y. Tateaki, H. Nakahara, and et al. Involvement of tumor necrosis facto-alpha receptor 1 and tumor necrosis factor-related apoptosis inducing ligand - (TRAIL) receptor-2/DR-5, but not Fas, in graft injury in live donor liver transplantation Transpl Int 17 2004 626 633
90. J.G. Brain, H. Robertson, E. Thompson, E.H. Humphreys, A. Gardner, T.A. Booth, and et al. Biliary epithelial senescence and plasticity in acute cellular rejection Am J Transplant 13 2013 1688 1702
91. J.G. Lunz III, S. Contrucci, K. Ruppert, N. Murase, J.J. Fung, T.E. Starzl, and et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection Am J Pathol 158 2001 1379 1390
92. M.C. Van den Heuvel, K.P. De Jong, M. Boot, M.J. Sloof, S. Popema, and A.S. Gouw Preservation of bile ductules mitigates bile duct loss Am J Transplant 6 2006 2660 2671
93. S.G. Hubscher, D.H. Adams, J.A. Buckels, P. McMaster, J. Neuberger, and E. Elias Massive haemorrhagic necrosis of the liver after liver transplantation J Clin Pathol 42 1989 360 370
94. G.W. Song, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon, and et al. Biliary strictures is the only concern in ABO-incompatible adult living donor transplantation in the rituximab era J Hepatol 61 2014 575 582
95. S.G. Hubscher What is the long-term outcome of the liver allograft? J Hepatol 55 2011 702 717
96. M. Sebagh, D. Samuel, T.M. Antonini, A. Coilly, D. Degli Esposti, B. Roche, and et al. Twenty-year protocol liver biopsies: invasive but useful for the management of liver recipients J Hepatol 56 2012 840 847
97. M. Castillo-Rama, M. Sebagh, E. Sasatomi, P. Randhawa, K. Isse, A.D. Salgarkar, and et al. "Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort Am J Transplant 13 2013 2966 2977
98. A.J. Demetris, and M. Sebagh Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl 14 2008 750 755
99. M. Sebagh, M. Castillo-Rama, D. Azoulay, A. Coilly, D. Delvart, M.A. Allard, and et al. Histological findings predictive of a diagnosis of de novo auto-immune hepatitis after liver transplantation in adults Transplantation 93 2013 670 678
100. Banff working group on liver allograft pathology Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance Liver Transpl 18 2012 1154 1170
101. M. Sebagh, D. Azoulay, B. Roche, E. Hoti, V. Karam, E. Teicher, and et al. Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation Liver Transpl 17 2011 798 808
102. J.P. Böttcher, P.A. Knolle, and D. Stabenow Mechanisms balancing tolerance and immunity in the liver Dig Dis 29 2011 384 390
103. I.N. Crispe The liver as a lymphoid organ Annu Rev Immunol 27 2009 147 163
104. R.Y. Calne, H.J. White, B.M. Hebertson, P.R. Millard, D.R. Davis, J.R. Salaman, and et al. Pig to baboon liver xenografts Lancet 1 1968 1176 1178
105. R.Y. Calne Immunological tolerance. The liver effect Immunol Rev 174 2000 280 282
106. R.Y. Calne, C.J. Watson, I.G. Brons, H. Makisalo, S.M. Metcalfe, V. Sriwatanawongsa, and et al. Tolerance of porcine renal allografts induced by donor spleen cells and seven day's treatment with cyclosporine Transplantation 57 1994 1433 1435
107. A. Sharland, Y. Yan, C. Wang, D.G. Bowen, J. Sun, A.G. Sheil, and et al. Evidence that apoptosis of activated T cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations which break tolerance Transplantation 68 1999 1736 1745
108. G.A. Bishop, C. Wang, A.F. Sharland, and G. McCaughan Spontaneous acceptance of liver transplants in rodents: evidence that liver leucocytes induce recipient T-cell death by neglect Immunol Cell Biol 80 2002 93 100
109. L.E. Holz, V. Benseler, D.G. Bowen, P. Bouillet, A. Strasser, L. O'Reilly, and et al. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death Gastroenterology 135 2008 989 997
110. W. Li, C.S. Kuhr, X.X. Zheng, K. Carper, A.W. Thomson, J.D. Reyes, and et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells Am J Transplant 8 2008 1639 1651
111. U. Steger, C.I. Kingsley, M. Karim, A.R. Bushell, and K.J. Wood CD25+CD4+ regulatory T cells develop in mice not only during spontaneous acceptance of liver allografts but also after acute allograft rejection Transplantation 82 2006 1202 1209
112. T.E. Starzl, A.J. Demetris, M. Trucco, N. Murase, C. Ricordi, S. Ildstad, and et al. Cell migration and chimerism after whole organ transplantation: the basis of graft acceptance Hepatology 17 1993 1127 1152
113. J. Reyes, A. Zeevi, H. Ramos, A. Tzakis, S. Todo, A.J. Demetris, and et al. Frequent achievement of a drug-free state after orthotopic liver transplantation Transplant Proc 25 1993 3315 3319
114. G.V. Mazariegos, J. Reyes, I.R. Marino, A.J. Demetris, B. Flynn, W. Irish, and et al. Weaning of immunosuppression in liver transplant recipients Transplantation 63 1997 243 249
115. R. Manez, S. Kusne, P. Linden, I. Gonzalez-Pinto, H. Bonet, D. Kramer, and et al. Temporary withdrawal of immunosuppression for life threatening infections after liver transplantation Transplantation 57 1994 149 151
116. P.C. Massarollo, S. Mies, E. Abdala, R.M. Leitao, and S. Raia Immunosuppression withdrawal for treatment of severe infections in liver transplantation Transplant Proc 30 1998 1472 1474
117. J. Devlin, D. Doherty, L. Thomson, T. Wong, P. Donaldson, B. Portmann, and et al. Defining the outcome of immunosuppression withdrawal after liver transplantation Hepatology 2 1998 926 933
118. J.A. Pons, J. Yélamos, P. Ramírez, M. Oliver-Bonet, A. Sánchez, M. Rodríguez-Gago, and et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression Transplantation 75 2003 1045 1047
119. J.D. Eason, A.J. Cohen, S. Nair, T. Alcantera, and G.E. Loss Tolerance: is it worth the risk? Transplantation 79 2005 1157 1159
120. M. Takatsuki, S. Uemoto, Y. Inomata, H. Egawa, T. Kiuchi, S. Fujita, and et al. Weaning of immunosuppression in living donor liver transplant recipients Transplantation 72 2001 449 454
121. P. Tryphonopoulos, A.G. Tzakis, D. Weppler, R. Garcia-Morales, T. Kato, J.R. Madariaga, and et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation Am J Transplant 5 2005 608 613
122. G. Tisone, G. Orlando, A. Cardillo, G. Palmieri, T.M. Manzia, L. Baiocchi, and et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence J Hepatol 44 2006 702 709
123. J. Lerut, and A. Sanchez-Fueyo An appraisal of tolerance in liver transplantation Am J Transplant 6 2006 1774 1780
124. S. Feng, U.D. Ekong, S.J. Lobritto, A.J. Demetris, J.P. Roberts, P. Rosenthal, and et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants JAMA 307 2012 283 930
125. C. Benítez, M.C. Londoño, R. Miquel, T.M. Manzia, J.G. Abraldes, J.J. Lozano, and et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients Hepatology 58 2013 1824 1835
126. T.M. Manzia, R. Angelico, L. Baiocchi, L. Toti, P. Ciano, G. Palmieri, and et al. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up Transpl Int 26 2013 259 266
127. F. Bohne, M.C. Londoño, C. Benítez, R. Miquel, M. Martínez-Llordella, C. Russo, and et al. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans Sci Trans Med 6 2014 242ra81
128. Yamashita K et al.: Successful withdrawal of Immunosuppression by a cell Therapy Using donor Ag-pulsed Tregs in Living Donor Liver Transplantation: An Update on Clinical Trial; abstract 0-72, ILTS London 2014.
129. A. Schlegel, P. Kron, R. Graf, P.A. Clavien, and P. Dutkowski Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation Ann Surg 260 2014 931 937
130. P.T. Moser, and H.C. Ott Recellularization of organs: what is the future for solid organ transplantation? Curr Opin Organ Transplant 19 2014 603 609
131. T. Hata, S. Uemoto, and E. Kobayashi Transplantable liver production plan Organogenesis 9 2013 235 238
132. E.K. Page, W.A. Dar, and S.J. Knechtle Biologics in organ transplantation Transpl Int 25 2012 707 719
133. S. Schlickeiser, D. Boës, M. Streitz, and B. Sawitzki The use of novel diagnostics to individualize immunosuppression following transplantation Transpl Int 2015 in press. http://dx.doi.org/10.1111/tri.12527
134. F. Bohne, M. Martínez-Llordella, J.J. Lozano, R. Miquel, C. Benítez, M.C. Londoño, and et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation J Clin Invest 122 2012 368 382
135. A.L. Putnam, N. Safinia, A. Medvec, M. Laszkowska, M. Wray, M.A. Mintz, and et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation Am J Transplant 13 2013 3010 3020
136. N. Safinia, J. Leech, M. Hernandez-Fuentes, R. Lechler, and G. Lombardi Promoting transplantation tolerance; adoptive regulatory T cell therapy Clin Exp Immunol 172 2013 158 168
137. J. Haarer, C.L. Johnson, Y. Soeder, and M.H. Dahlke Caveats of mesenchymal stem cell therapy in solid organ transplantation Transpl Int 28 2015 1 9
138. M. Franquesa MiSOT Study Group Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials Transplantation 96 2013 234 238
139. T. Kawai, and D.H. Sachs Tolerance induction: hematopoietic chimerism Curr Opin Organ Transplant 18 2013 402 407
140. J. Koreth, Kim H.T. Matsuoka, S.M. McDonough, B. Bindra, E.P. Alyea, P. Armand, and et al. Interleukin-2 and regulatory T cells in graft-versus-host disease N Engl J Med 365 2011 2055 2066
141. A. Hartemann, G. Bensimon, C.A. Payan, S. Jacqueminet, O. Bourron, N. Nicolas, and et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 1 2013 295 305
142. A. Peloso, R. Katari, J.P. Zambon, A. Defrancesco, A. Moore, C. Holton, and et al. Abdominal organ bioengineering: current status and future perspectives Minerva Chir 70 2015 43 55